for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AVEO Pharmaceuticals, Inc.

AVEO.OQ

Latest Trade

0.96USD

Change

0.00(+0.24%)

Volume

56,237

Today's Range

0.96

 - 

0.97

52 Week Range

0.50

 - 

3.58

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.96
Open
0.96
Volume
56,237
3M AVG Volume
65.76
Today's High
0.97
Today's Low
0.96
52 Week High
3.58
52 Week Low
0.50
Shares Out (MIL)
160.74
Market Cap (MIL)
159.14
Forward P/E
-10.53
Dividend (Yield %)
--

Latest Developments

More

Aveo Oncology Says 20 Patients Remain Progression Free On Tivozanib Arm

Aveo Pharmaceuticals Says Matthew Dallas, Chief Financial Officer, Will Resign From Company Effective As Of September 26

Aveo Q2 Loss Per Share $0.02

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).

Industry

Biotechnology & Drugs

Contact Info

1 Broadway Fl 14

+1.617.5312130

http://www.aveooncology.com/

Executive Leadership

Michael P. Bailey

President, Chief Executive Officer, Director

Matthew Dallas

Chief Financial Officer

Karuna Rubin

Senior Vice President, General Counsel

Nikhil Mehta

Senior Vice President - Regulatory and Quality Assurance

Mike Ferraresso

Vice President - Business Analytics and Commercial Operations

Key Stats

2.60 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.390

2017

-0.610

2018

-0.040

2019(E)

-0.094
Price To Earnings (TTM)
--
Price To Sales (TTM)
25.41
Price To Book (MRQ)
97.45
Price To Cash Flow (TTM)
7.29
Total Debt To Equity (MRQ)
1,184.57
LT Debt To Equity (MRQ)
683.77
Return on Investment (TTM)
-22.84
Return on Equity (TTM)
-9.49

Latest News

UPDATE 2-Australia's Aveo reveals Canada's Brookfield as bidder

* Brookfield's takeover talks "opportunistic" - analyst (Rewrites copy, adds analyst comment)

BRIEF-Aveo Pharmaceuticals Says Co Entered Agreement With Novartis International Pharmaceutical Regarding Aveo's AV380 Program

* AVEO PHARMACEUTICALS INC - ON DEC. 18, AVEO ENTERED AGREEMENT WITH NOVARTIS INTERNATIONAL PHARMACEUTICAL REGARDING AVEO’S AV380 PROGRAM

BRIEF-Aveo Reports Q1 Loss Per Share $0.08

* AVEO REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Aveo Quarterly Loss Per Share $0.08

* AVEO REPORTS FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Aveo Pharmaceuticals ‍Entered Into Sales Agreement With Leerink Partners

* AVEO PHARMACEUTICALS SAYS ENTERED INTO A SALES AGREEMENT WITH LEERINK PARTNERS - SEC FILING

BRIEF-AVEO Says EUSA Pharma Granted Positive NICE Recommendation For Fotivda

* AVEO ANNOUNCES EUSA PHARMA GRANTED POSITIVE NICE RECOMMENDATION FOR FOTIVDA® (TIVOZANIB) AS FIRST LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA

BRIEF-Aveo Pharma Entered Into Binding MoU With Class Representatives Regarding Settlement Of A 2013 Class Action Lawsuit

* AVEO PHARMACEUTICALS - ENTERED INTO BINDING MOU WITH CLASS REPRESENTATIVES BOB LEVINE & WILLIAM WINDHAM REGARDING SETTLEMENT OF A 2013 CLASS ACTION LAWSUIT

BRIEF-Aveo Oncology Announces Clinical Updates To Tivozanib And Ficlatuzumab Programs

* AVEO ONCOLOGY ANNOUNCES CLINICAL UPDATES TO TIVOZANIB AND FICLATUZUMAB PROGRAMS

BRIEF-Aveo Pharmaceuticals Files For Mixed Shelf Of Upto $200 Mln

* AVEO PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING Source text: [http://bit.ly/2Bzw8T1] Further company coverage:

BRIEF-AVEO PHARMACEUTICALS REPORTS Q3 LOSS PER SHARE $0.22

* AVEO REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Aveo Pharmaceuticals- Tivo-3 study will continue as planned without modification

* Aveo Pharmaceuticals Inc - announces completion of Tivo-3 study futility analysis with no changes to study protocol

BRIEF-AVEO Oncology and EUSA Pharma announce TiNivo combination study opt-in

* Aveo Pharmaceuticals Inc - EUSA Pharma has agreed to pay AVEO up to $388 million in future milestone payments and research and development funding

BRIEF-Aveo Oncology announces Fotivda approved in the EU for the treatment of advanced renal cell carcinoma

* Aveo Oncology announces Fotivda® (tivozanib) approved in the European Union for the treatment of advanced renal cell carcinoma

BRIEF-Aveo Pharmaceuticals Inc Q2 loss per share $0.30

* Aveo reports second quarter 2017 financial results and provides business update

BRIEF-Aveo Oncology gets $14 mln from Hercules Credit Facility and at-the-market stock offerings

* Aveo Oncology announces $14m in aggregate gross proceeds from Hercules Credit Facility and at-the-market stock offerings

EU regulators greenlight U.S. biotech Aveo's kidney cancer drug

European regulators on Friday recommended the approval of Aveo Pharmaceuticals Inc's drug to treat kidney cancer, marking a big victory for the U.S. biotech that has faced a number of setbacks in bringing the drug to the market.

BRIEF-Aveo Oncology announces phase 1/2 tinivo trial

* Aveo Oncology announces phase 1/2 tinivo trial of tivozanib and opdivo® (nivolumab) in RCC advances to phase 2

BRIEF-Aveo appoints Matthew Dallas chief financial officer

* Aveo announces appointment of Matthew Dallas as chief financial officer

BRIEF-Aveo announces submission of response to Tivozanib marketing authorization application day 180 list of outstanding issues

* Aveo announces submission of response to tivozanib marketing authorization application day 180 list of outstanding issues

BRIEF-Aveo announces pricing of $15 mln public offering of common stock

* Aveo announces pricing of $15.0 million public offering of common stock

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up